988 related articles for article (PubMed ID: 29045207)
1. Tofacitinib for Psoriatic Arthritis in Patients with an Inadequate Response to TNF Inhibitors.
Gladman D; Rigby W; Azevedo VF; Behrens F; Blanco R; Kaszuba A; Kudlacz E; Wang C; Menon S; Hendrikx T; Kanik KS
N Engl J Med; 2017 Oct; 377(16):1525-1536. PubMed ID: 29045207
[TBL] [Abstract][Full Text] [Related]
2. Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial.
Burmester GR; Blanco R; Charles-Schoeman C; Wollenhaupt J; Zerbini C; Benda B; Gruben D; Wallenstein G; Krishnaswami S; Zwillich SH; Koncz T; Soma K; Bradley J; Mebus C;
Lancet; 2013 Feb; 381(9865):451-60. PubMed ID: 23294500
[TBL] [Abstract][Full Text] [Related]
3. Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: a randomized trial.
Kremer J; Li ZG; Hall S; Fleischmann R; Genovese M; Martin-Mola E; Isaacs JD; Gruben D; Wallenstein G; Krishnaswami S; Zwillich SH; Koncz T; Riese R; Bradley J
Ann Intern Med; 2013 Aug; 159(4):253-61. PubMed ID: 24026258
[TBL] [Abstract][Full Text] [Related]
4. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis.
Fleischmann R; Kremer J; Cush J; Schulze-Koops H; Connell CA; Bradley JD; Gruben D; Wallenstein GV; Zwillich SH; Kanik KS;
N Engl J Med; 2012 Aug; 367(6):495-507. PubMed ID: 22873530
[TBL] [Abstract][Full Text] [Related]
5. Tofacitinib versus methotrexate in rheumatoid arthritis.
Lee EB; Fleischmann R; Hall S; Wilkinson B; Bradley JD; Gruben D; Koncz T; Krishnaswami S; Wallenstein GV; Zang C; Zwillich SH; van Vollenhoven RF;
N Engl J Med; 2014 Jun; 370(25):2377-86. PubMed ID: 24941177
[TBL] [Abstract][Full Text] [Related]
6. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis.
van Vollenhoven RF; Fleischmann R; Cohen S; Lee EB; García Meijide JA; Wagner S; Forejtova S; Zwillich SH; Gruben D; Koncz T; Wallenstein GV; Krishnaswami S; Bradley JD; Wilkinson B;
N Engl J Med; 2012 Aug; 367(6):508-19. PubMed ID: 22873531
[TBL] [Abstract][Full Text] [Related]
7. Oral tofacitinib efficacy, safety and tolerability in Japanese patients with moderate to severe plaque psoriasis and psoriatic arthritis: A randomized, double-blind, phase 3 study.
Asahina A; Etoh T; Igarashi A; Imafuku S; Saeki H; Shibasaki Y; Tomochika Y; Toyoizumi S; Nagaoka M; Ohtsuki M;
J Dermatol; 2016 Aug; 43(8):869-80. PubMed ID: 26875540
[TBL] [Abstract][Full Text] [Related]
8. Tofacitinib Versus Biologic Treatments in Patients With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Tumor Necrosis Factor Inhibitors: Results From a Network Meta-analysis.
Vieira MC; Zwillich SH; Jansen JP; Smiechowski B; Spurden D; Wallenstein GV
Clin Ther; 2016 Dec; 38(12):2628-2641.e5. PubMed ID: 27889300
[TBL] [Abstract][Full Text] [Related]
9. Tofacitinib, an oral Janus kinase inhibitor, as monotherapy or with background methotrexate, in Japanese patients with rheumatoid arthritis: an open-label, long-term extension study.
Yamanaka H; Tanaka Y; Takeuchi T; Sugiyama N; Yuasa H; Toyoizumi S; Morishima Y; Hirose T; Zwillich S
Arthritis Res Ther; 2016 Jan; 18():34. PubMed ID: 26818974
[TBL] [Abstract][Full Text] [Related]
10. Tofacitinib in Combination With Conventional Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis: Patient-Reported Outcomes From a Phase III Randomized Controlled Trial.
Strand V; Kremer JM; Gruben D; Krishnaswami S; Zwillich SH; Wallenstein GV
Arthritis Care Res (Hoboken); 2017 Apr; 69(4):592-598. PubMed ID: 27565000
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of tofacitinib in US and non-US rheumatoid arthritis patients: pooled analyses of phase II and III.
Cohen SB; Koenig A; Wang L; Kwok K; Mebus CA; Riese R; Fleischmann R
Clin Exp Rheumatol; 2016; 34(1):32-6. PubMed ID: 26575982
[TBL] [Abstract][Full Text] [Related]
12. Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis.
Sandborn WJ; Ghosh S; Panes J; Vranic I; Su C; Rousell S; Niezychowski W;
N Engl J Med; 2012 Aug; 367(7):616-24. PubMed ID: 22894574
[TBL] [Abstract][Full Text] [Related]
13. A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone.
Kremer JM; Cohen S; Wilkinson BE; Connell CA; French JL; Gomez-Reino J; Gruben D; Kanik KS; Krishnaswami S; Pascual-Ramos V; Wallenstein G; Zwillich SH
Arthritis Rheum; 2012 Apr; 64(4):970-81. PubMed ID: 22006202
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of tofacitinib in patients with rheumatoid arthritis stratified by background methotrexate dose group.
Fleischmann R; Mease PJ; Schwartzman S; Hwang LJ; Soma K; Connell CA; Takiya L; Bananis E
Clin Rheumatol; 2017 Jan; 36(1):15-24. PubMed ID: 27734232
[TBL] [Abstract][Full Text] [Related]
15. Tofacitinib, an oral Janus kinase inhibitor, for the treatment of Latin American patients with rheumatoid arthritis: Pooled efficacy and safety analyses of Phase 3 and long-term extension studies.
Radominski SC; Cardiel MH; Citera G; Goecke A; Jaller JJ; Lomonte ABV; Miranda P; Velez P; Xibillé D; Kwok K; Rojo R; García EG
Reumatol Clin; 2017; 13(4):201-209. PubMed ID: 27317492
[TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of tofacitinib, an oral janus kinase inhibitor, for the treatment of rheumatoid arthritis in open-label, longterm extension studies.
Wollenhaupt J; Silverfield J; Lee EB; Curtis JR; Wood SP; Soma K; Nduaka CI; Benda B; Gruben D; Nakamura H; Komuro Y; Zwillich SH; Wang L; Riese RJ
J Rheumatol; 2014 May; 41(5):837-52. PubMed ID: 24692527
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of tofacitinib by background methotrexate dose in psoriatic arthritis: post hoc exploratory analysis from two phase III trials.
Kivitz AJ; FitzGerald O; Nash P; Pang S; Azevedo VF; Wang C; Takiya L
Clin Rheumatol; 2022 Feb; 41(2):499-511. PubMed ID: 34510295
[TBL] [Abstract][Full Text] [Related]
18. Tofacitinib: The First Janus Kinase (JAK) inhibitor for the treatment of rheumatoid arthritis.
Vyas D; O'Dell KM; Bandy JL; Boyce EG
Ann Pharmacother; 2013 Nov; 47(11):1524-31. PubMed ID: 24285764
[TBL] [Abstract][Full Text] [Related]
19. Changes in Lipid Levels and Incidence of Cardiovascular Events Following Tofacitinib Treatment in Patients With Psoriatic Arthritis: A Pooled Analysis Across Phase III and Long-Term Extension Studies.
Gladman DD; Charles-Schoeman C; McInnes IB; Veale DJ; Thiers B; Nurmohamed M; Graham D; Wang C; Jones T; Wolk R; DeMasi R
Arthritis Care Res (Hoboken); 2019 Oct; 71(10):1387-1395. PubMed ID: 31112005
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of tofacitinib for active rheumatoid arthritis with an inadequate response to methotrexate or disease-modifying antirheumatic drugs: a meta-analysis of randomized controlled trials.
Song GG; Bae SC; Lee YH
Korean J Intern Med; 2014 Sep; 29(5):656-63. PubMed ID: 25228842
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]